Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.

Boehringer Ingelheim subsidiary NBE Therapeutics has opened its new antibody-drug conjugates (ADC) R&D facility in Basel, ...

Late-stage pipeline products anticipated to reach the uveitis market during the forecast period will introduce new mechanisms ...

The EC has approved Daiichi Sankyo and AstraZeneca’s Enhertu for use as a single agent to treat adults with certain breast ...

This week, the Trump administration followed through on its planned mass layoffs at agencies under the US Department of ...